Novartis | NVS - Ebit


Novartis reported $4.18B in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bausch Health Companies USD 489M 230M Mar/2026
Biogen USD 514.3M 502.8M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Canopy Growth CAD -145.65M 132.99M Mar/2026
Corcept Therapeutics USD -49.6M 54.09M Mar/2026
Drreddys Laboratories INR 3.05B 13.32B Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Glaxosmithkline GBP 2.31B 14.92M Mar/2026
J&J USD 7.48B 860M Jun/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.18B 118M Mar/2026
Novartis USD 4.18B 118M Mar/2026
Pacira USD 4.62M 1.43M Mar/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 75.49M 7M Mar/2026
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
Sanofi EUR 2.18B 1.56B Mar/2026
Supernus Pharmaceuticals USD -35.25M 49.07M Mar/2026
Zoetis USD 842M 7M Mar/2026